DYN Dyne Therapeutics
- 27.680
- -1.070-3.72%
- 27.760
- +0.080+0.29%
Dyne Therapeutics News
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dyne Therapeutics Price Target Maintained With a $31.00/Share by Chardan Capital
Dyne Therapeutics Price Target Maintained With a $31.00/Share by Chardan Capital
Chardan Capital: Maintaining the Dyne Therapeutics (DYN.US) rating, adjusted from buy to buy rating, and adjusted the target price from $31.00 to $31.00.
Chardan Capital: Maintaining the Dyne Therapeutics (DYN.US) rating, adjusted from buy to buy rating, and adjusted the target price from $31.00 to $31.00.
Dyne Therapeutics, Inc. (NASDAQ:DYN) Is Largely Controlled by Institutional Shareholders Who Own 53% of the Company
Key Insights Significantly high institutional ownership implies Dyne Therapeutics' stock price is sensitive to their trading actions 51% of the business is held by the top 10 shareholders Insider
Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $47 Price Target
Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics with a Outperform and maintains $47 price target.
Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)
Robust Financial Health and Promising Clinical Trials Bolster Buy Rating for Dyne Therapeutics
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns With Analyst Projections
HC Wainwright & Co. : The Dyne Therapeutics (DYN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $36.00.
HC Wainwright & Co. : The Dyne Therapeutics (DYN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $36.00.
HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $36 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Dyne Therapeutics with a Buy and maintains $36 price target.
Optimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy Data
Dyne Therapeutics (DYN.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.81 dollars, previous value of -0.78 dollars, expected value of -0.80 dollars.
Dyne Therapeutics (DYN.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.81 dollars, previous value of -0.78 dollars, expected value of -0.80 dollars.
Dyne Therapeutics 1Q Loss/Shr 81c >DYN
Dyne Therapeutics 1Q Loss/Shr 81c >DYN
Dyne Therapeutics 1Q Loss $65.6M >DYN
Dyne Therapeutics 1Q Loss $65.6M >DYN
Press Release: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Ant
Dyne Therapeutics Price Target Announced at $40.00/Share by Morgan Stanley
Dyne Therapeutics Price Target Announced at $40.00/Share by Morgan Stanley
Dyne Therapeutics (DYN.US) was covered for the first time by Damo and was given an increase in holdings rating, with a target price of $40.00.
Dyne Therapeutics (DYN.US) was covered for the first time by Damo and was given an increase in holdings rating, with a target price of $40.00.
Morgan Stanley Initiates Coverage On Dyne Therapeutics With Overweight Rating, Announces Price Target of $40
Morgan Stanley analyst Michael Ulz initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating and announces Price Target of $40.
Analysis
Price Target
No Data
